Active-ingredient Dossier
Glycopyrronium Bromide
Active-ingredient Dossier for Glycopyrronium Bromide (anticholinergic agent). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: AXHIDROX
- Brand: ENERZAIR BREEZHALER
- Brand: ROBINUL
- Brand: GLYCONEO
- Brand: GLYCOPYRROLATE ACCORD
- Brand: GLYCOPYRRONIUM-AFT
- Therapeutic area: Other
- Therapeutic area: Neurology
- Therapeutic area: Dermatology
What is
Glycopyrronium Bromide Glycopyrronium Bromide is an anticholinergic agent.
Australian brands containing
Glycopyrronium Bromide — AXHIDROX — SEEBRI — ROBINUL — ENERZAIR BREEZHALER — GLYCONEO — GLYCOPYRROLATE ACCORD — GLYCOPYRRONIUM-AFT — NOVISTIG
Therapeutic areas
Glycopyrronium Bromide is registered in multiple therapeutic areas: Respiratory (3 brands), Cardiology (3 brands), Neurology (2 brands), Dermatology (1 brand), and Other (1 brand).
Sponsor landscape
The ingredient is marketed by eight sponsors: Novartis Pharmaceuticals, KSJ Pharmatech, Actor Pharmaceuticals, Accord Healthcare, AFT Pharmaceuticals, and Boucher & Muir.
PBS and regulatory activity
Three brands have PBAC outcomes on record, with the latest outcome dated 1 November 2025. One brand has an AusPAR on record, with the latest dated 31 October 2012.